01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Competing interests
Authors’ contributions
Background
Methods
Patients
Statistical analysis
Results
Demographic characteristics
UCD
|
MCD
|
P
|
|
---|---|---|---|
Age (mean, years)
|
30.44 ± 8.00
|
41.56 ± 13.50
|
0.004
|
Gender
|
|||
Male
|
8/50%
|
11/34.4%
|
0.2967
|
Female
|
8/50%
|
21/65.6%
|
|
Pathological type
|
|||
Hyaline vascular
|
3/18.75%
|
16/50%
|
|
Plasma cell
|
12/75%
|
12/37.5%
|
0.049
|
Mixed
|
1/6.25%
|
4/12.5%
|
|
Non-symptomatic
|
8/50%
|
1/3.1%
|
<0.001
|
Fever
|
0
|
16/50%
|
<0.001
|
Pleural effusion
|
2/12.5%
|
13/40.6%
|
0.0475
|
Hepatomegaly and/or splenomegaly
|
0
|
16/50%
|
<0.001
|
Anemia
|
3/18.8%
|
15/46.9%
|
0.0578
|
Hemoglobin (g/l)
|
133.13 ± 29.70
|
108.66 ± 26.60
|
0.0059
|
Platelet (×10
9
/l)
|
|||
>300 × 10
9
/l
|
4/25%
|
12/37.5%
|
0.6785
|
<100 × 10
9
/l
|
1/8.3%
|
2/10%
|
|
Hypoalbuminia
|
4/25%
|
22/68.8%
|
0.0041
|
Elevation of serum LDH
‡
|
5/30%
|
5/16.1%
|
0.6731
|
HIV-Ab
|
|||
Not done
|
0
|
6/18.75%
|
|
Negative
|
16/100%
|
26/100% (n = 26)
|
1
|
Chemotherapy cases
|
0
|
28/87.5%
|
<0.001
|
Outcomes
|
|||
Cured
|
16/100%
|
0
|
|
Improved
|
0
|
18/56.3%
|
|
Stable
|
0
|
7/21.9%
|
<0.001
|
Died
|
0
|
3/9.4%
|
|
Lost follow-up
|
0
|
4/12.5%
|
Clinical and radiological manifestations
Chest CT characters
|
n/%
|
---|---|
UCDs (n = 16)
|
|
Solitary mass (n = 16,100%)
|
|
Location
|
|
Mediastinum
|
11/68.75%
|
Lung hilum
|
3/18.75%
|
Intrapulmonary fissure
|
1/6.25%
|
Lung
|
1/6.25%
|
Size
|
(113.56 ± 81.31) cm
3 [(20–336) cm
3]
|
Punctate calcification in the mass
|
5/31.25%
|
Enhancement in the contrast-enhanced CT (n = 14)
Ф
|
|
Pattern
|
|
Homogeneous
|
12/85.71%
|
Heterogeneous
|
2/14.29%
|
Degree
|
|
High
|
13/92.86%
|
Moderate
|
1/7.14%
|
Pleural effusion
|
2/14.29%
|
MCDs (n = 32)
|
|
Lymphadenopathy
|
|
Location
|
|
Diffuse lymphadenopathy in the hilum and/or mediastinum
|
32/100%
|
Superficial lymphadenopathy
|
20/62.5%
|
Cervical LNs
|
20/62.5%
|
Superclavicular LNs
|
4/12.5%
|
Axillary LNs
|
12/37.5%
|
Diffuse parenchymal lung disease
|
14/43.75%
|
Multiple nodules in different size
|
6/18.75%
|
Multiple patchy infiltrates
|
6/18.75%
|
GGO
|
5/15.63%
|
LIP-like pattern
|
3/9.38%
|
Consolidation
|
3/9.38%
|
Bronchiolitis obliterans
|
1/3.12%
|
Mass
|
3/9.38%
|
Mediastinal mass
|
2/6.25%
|
Hilar mass
|
1/3.12%
|
Pleural effusion
|
13/40.6%
|
Laboratory tests
Pathological features
UCD (n = 16)
|
MCD (n = 32)
|
|
---|---|---|
Thoracic surgery
|
||
Open thoracic surgery
|
16/100%
|
0
|
VATS
ξ
|
1/16.67%
|
8/25%
|
Abdominal surgery
|
0
|
1/3.12%
|
Superficial LN biopsy
|
0
|
21/65.6%
|
Cervical LN
|
0
|
9/28.13%
|
Axillary LN
|
0
|
6/18.75%
|
Supratrochlear LN
|
0
|
1/3.12%
|
Percutaneous lung biopsy
|
0
|
2/6.25%
|